1310 Chesapeake Terrace
433 articles with Accuray Inc.
Accuray CyberKnife® Robotic Radiotherapy Platform Expands Range of Neurological Indications That Can Be Effectively Treated With Stereotactic Radiosurgery
Accuray Incorporated (NASDAQ: ARAY) announced today that more than two decades of globally-driven clinical data support the use of the company's CyberKnife® robotic radiotherapy platform for the delivery of stereotactic radiosurgery (SRS) treatments for neurological diseases.
Company to present on Tuesday, November 16th, 2021 at 6:20 am PT / 9:20 am ET
Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter of fiscal 2022 ended September 30, 2021 .
Accuray CyberKnife® Robotic Radiotherapy Platform Could Significantly Improve Survival in Early-Stage Breast Cancer Patients
Accuray Incorporated (NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast irradiation (APBI) delivered using the Accuray CyberKnife
Accuray Announces Preliminary First Quarter Fiscal 2022 Financial Results and Raises FY22 Revenue Guidance to range between $420 million to $427 million
Accuray Incorporated, announced preliminary financial results for the first quarter of fiscal 2022 ended September 30, 2021.
Accuray Incorporated (NASDAQ: ARAY) announced today the company is showcasing its new VOLO™ Ultra for the Radixact ® System, at ASTRO 2021.
Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2022, ended September 30, 2021 , after the market close on Wednesday, November 3, 2021
Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host an Analyst & Investor Meeting on Monday, October 25, 2021 , in conjunction with the American Society of Radiation Oncology (ASTRO) Annual Meeting.
Nagoya City University Hospital is First in Japan to Treat Cancer Patients Using the Accuray Radixact® System with ClearRT™ Helical Fan-Beam kVCT Imaging
Accuray Incorporated (NASDAQ: ARAY) announced today that the Nagoya City University Hospital in Aichi has treated the first cancer patient in Japan using the Radixact ® System with ClearRT
Accuray Incorporated announced the appointment of Mika Nishimura to the company's Board of Directors, effective as of August 17, 2021.
Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2021 .
Hong Kong Sanatorium & Hospital Transforms Cancer Care in Asia with Treatment of First Patient Using the Accuray Radixact® System and ClearRT™ Helical Fan-Beam kVCT Imaging
Accuray Incorporated (NASDAQ: ARAY) announced today that the medical care team at Hong Kong Sanatorium & Hospital (HKSH) in Hong Kong treated the first cancer patient in using the Radixact® System, the next-generation TomoTherapy® platform, with ClearRT™ helical fan-beam kVCT imaging.
Accuray Incorporated will report financial results for the fourth quarter and fiscal year 2021, ended June 30, 2021, after the market close on Wednesday, August 11, 2021.
Beloved Family Pet's Lung Cancer is Treated with Targeted Radiotherapy Using the Accuray Radixact® System with Synchrony® Technology
The University of Wisconsin-Madison School of Veterinary Medicine team is advancing cancer care as the first to treat an animal using the Radixact® System with Synchrony®.
Accuray (NASDAQ: ARAY) announced today that Suzanne Winter has been promoted to president, effective as of July 1, 2021 .
Accuray Expands CyberKnife® System Versatility with Integration of RaySearch's RayStation Treatment Planning System
Accuray Incorporated announced the launch of RayStation* treatment planning support for the company's CyberKnife® M6™** and S7™** Robotic, Radiotherapy Systems.
Accuray Expands Commercialization of ClearRT™ Helical Fan-Beam kVCT Imaging for the Radixact® System with CE Mark Certification
Expands Global Access to Exceptional Quality Diagnostic-like CT Images for Medical Care Teams Using the Radixact System.
Accuray Incorporated announced that it has entered into privately negotiated agreements with the holders of its existing 3.75% senior convertible notes due 2022 to exchange an aggregate of $82.1 million principal amount of 2022 Notes for approximately $97.1 million aggregate principal amount of a new series of 3.75% senior convertible notes due 2026.
Accuray Incorporated reported, as required by NASDAQ Listing Rules, equity inducement awards to Jean-Philippe Pignol, M.D., Ph.D., the company's new Chief Medical & Technology Officer.
Accuray Customers Achieve Top Scores in AAPM MArkerless Lung Target Tracking CHallenge (MATCH) Using Synchrony® Technology on the Radixact® and CyberKnife® Systems
- American Association of Physicists in Medicine (AAPM) Grand Challenge MATCH event was designed to evaluate the potential to track lung tumor motion without fiducial markers in real-time during radiation therapy - Results demonstrate exceptional accuracy is achievable with the Accuray-only Synchrony® Lung Tracking™ with Respiratory Modeling Technology